Qualified kidney injury biomarkers demonstrate value during early clinical drug development
Toxicological Sciences · 2024
DOI: 10.1093/toxsci/kfae088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2024. Verfasst von Kodihalli C Ravindra und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States. Hauptthemen laut MEDLINE: Biomarkers, Drug Development, Acute Kidney Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Drug-induced kidney injury (DIKI) is of significant concern, both during drug development and in clinical practice. We report a patient-centric approach for clinical implementation of the FDA-qualified kidney safety biomarker panel, highlighting Phase 1 and 2 trials for candidate therapeutics in Pfizer’s portfolio (PFE-1 and PFE-2, respectively) that induced kidney tubular injury in rat toxicity studies. Clusterin (CLU), cystatin-C (CysC), kidney injury molecule-1 (KIM-1), N-acetyl-beta-d-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), and osteopontin (OPN) were measured in urine samples from (i) Phase 1 healthy volunteers (HVs; n = 12) dosed with PFE-1, (ii) Phase 2 rheumatoid arthritis (RA) patients (n = 266) dosed with PFE-2, (iii) lupus patients on standard-of-care therapies (n = 121), and (iv) healthy volunteers (n = 60). The FDA-defined composite measure (CM), calculated as the geometric mean response across the 6 biomarkers, was increased ∼30% in HVs administered 100 mg PFE-1 relative to placebo, providing evidence of DIKI. In contrast, the CM for RA patients dosed with PFE-2 was comparable to placebo controls, helping to de-risk the concern for DIKI at clinically relevant doses. Comparing individual biomarker concentrations across disease states revealed that CLU, KIM-1, NAG, NGAL, and OPN are elevated in the urine of RA and lupus patients (those without severe active proliferative lupus nephritis) relative to HVs. Overall, these case studies demonstrate the value of using the FDA-qualified kidney biomarker panel to guide risk assessment, dose selection, and clinical decision making for novel therapeutics, both in HVs and patient populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Safety Research and Development, Pfizer Inc., Groton, CT 06340, United States.
- Department of Translational Clinical Sciences, Pfizer Inc., Groton, CT 06340, United States.
- Department of Global Biometrics and Data Management, Pfizer Inc., Cambridge, MA 02139, United States.
- Department of Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, United States.
- Department of Inflammation and Immunology, Pfizer Inc., Collegeville, PA 19426, United States.
- Department of Internal Medicine, Pfizer Inc., Cambridge, MA 02139, United States.
ORCID-Profile: Kodihalli C Ravindra, Kelly A Fader
Zitieren
APA
Ravindra, K. C., Fader, K. A., Potter, D., Radi, Z. A., Friedman, G. S., Brenneman, K. A., Amin, N. B., Weiss, R., Danto, S. I., Page, K., Ramaiah, S. K., & Vaidya, V. S. (2024). Qualified kidney injury biomarkers demonstrate value during early clinical drug development. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfae088
Vancouver
Ravindra KC, Fader KA, Potter D, Radi ZA, Friedman GS, Brenneman KA, et al. Qualified kidney injury biomarkers demonstrate value during early clinical drug development. Toxicological Sciences. 2024. doi:10.1093/toxsci/kfae088
BibTeX
@article{Ravindra2024,
author = {Ravindra, Kodihalli C and Fader, Kelly A and Potter, David and Radi, Zaher A and Friedman, Gary S and Brenneman, Karrie A and Amin, Neeta B and Weiss, Roberta and Danto, Spencer I and Page, Karen and Ramaiah, Shashi K and Vaidya, Vishal S},
title = {Qualified kidney injury biomarkers demonstrate value during early clinical drug development},
journal = {Toxicological Sciences},
year = {2024},
doi = {10.1093/toxsci/kfae088}
}
EUVIMED